TSE:MDNA

Medicenna Therapeutics Competitors

C$4.82
-0.03 (-0.62 %)
(As of 04/20/2021 03:59 PM ET)
Add
Compare
Today's Range
C$4.74
Now: C$4.82
C$4.93
50-Day Range
C$4.46
MA: C$4.99
C$5.38
52-Week Range
C$3.06
Now: C$4.82
C$7.25
Volume67,909 shs
Average Volume113,187 shs
Market CapitalizationC$254.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Medicenna Therapeutics (TSE:MDNA) Vs. APS, BU, BLU, TH, NRI, and PLI

Should you be buying MDNA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Medicenna Therapeutics, including Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Aptose Biosciences (TSE:APS) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aptose Biosciences and Medicenna Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Medicenna Therapeutics0000N/A

Aptose Biosciences presently has a consensus price target of C$12.00, indicating a potential upside of 97.37%. Given Aptose Biosciences' higher probable upside, research analysts plainly believe Aptose Biosciences is more favorable than Medicenna Therapeutics.

Profitability

This table compares Aptose Biosciences and Medicenna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Medicenna TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Aptose Biosciences and Medicenna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.84)-7.20
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60

Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats Medicenna Therapeutics on 3 of the 4 factors compared between the two stocks.

Medicenna Therapeutics (TSE:MDNA) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and Burcon NutraScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
Burcon NutraScience00103.00

Burcon NutraScience has a consensus price target of C$5.00, indicating a potential downside of 1.19%. Given Burcon NutraScience's higher probable upside, analysts clearly believe Burcon NutraScience is more favorable than Medicenna Therapeutics.

Profitability

This table compares Medicenna Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Earnings & Valuation

This table compares Medicenna Therapeutics and Burcon NutraScience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60
Burcon NutraScienceC$12,045.0044,992.20C$107,101.00C$0.005,060.00

Burcon NutraScience has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Medicenna Therapeutics on 5 of the 5 factors compared between the two stocks.

Medicenna Therapeutics (TSE:MDNA) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
BELLUS Health01202.67

Profitability

This table compares Medicenna Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
BELLUS HealthN/AN/AN/A

Earnings & Valuation

This table compares Medicenna Therapeutics and BELLUS Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60
BELLUS HealthC$15,000.0029,298.04C$-52,720,801.00C($0.67)-8.34

Medicenna Therapeutics has higher earnings, but lower revenue than BELLUS Health. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Summary

BELLUS Health beats Medicenna Therapeutics on 3 of the 4 factors compared between the two stocks.

Medicenna Therapeutics (TSE:MDNA) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Medicenna Therapeutics and Theratechnologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60
TheratechnologiesC$65.76 million6.47C$-35,948,380.00C($0.38)-11.84

Medicenna Therapeutics has higher earnings, but lower revenue than Theratechnologies. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicenna Therapeutics and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
TheratechnologiesN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and Theratechnologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
Theratechnologies02002.00

Theratechnologies has a consensus price target of C$3.75, indicating a potential downside of 16.67%. Given Theratechnologies' higher probable upside, analysts clearly believe Theratechnologies is more favorable than Medicenna Therapeutics.

Summary

Theratechnologies beats Medicenna Therapeutics on 3 of the 4 factors compared between the two stocks.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Valuation and Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Medicenna Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.29C$-6,980,844.00C($0.61)-57.68
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60

Medicenna Therapeutics has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Medicenna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
Medicenna TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and Medicenna Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
Medicenna Therapeutics0000N/A

ProMetic Life Sciences (TSE:PLI) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Valuation and Earnings

This table compares ProMetic Life Sciences and Medicenna Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
Medicenna TherapeuticsN/AN/AN/AC($0.31)-15.60

Medicenna Therapeutics has lower revenue, but higher earnings than ProMetic Life Sciences. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProMetic Life Sciences and Medicenna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
Medicenna TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ProMetic Life Sciences and Medicenna Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Medicenna Therapeutics0000N/A

Summary

ProMetic Life Sciences beats Medicenna Therapeutics on 2 of the 3 factors compared between the two stocks.


Medicenna Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
APS
Aptose Biosciences
1.3$6.08-4.8%C$566.20 millionN/A-7.20
BU
Burcon NutraScience
1.2$5.06-0.2%C$543.00 millionC$12,045.005,060.00
BLU
BELLUS Health
0.5$5.61-3.2%C$453.57 millionC$15,000.00-8.34
Theratechnologies logo
TH
Theratechnologies
0.7$4.50-0.2%C$424.76 millionC$65.76 million-11.84Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.36-0.3%C$402.68 millionC$76.09 million-57.68
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22
NEPT
Neptune Wellness Solutions
1.2$1.47-8.2%C$263.13 millionC$52.78 million-1.09Gap Up
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89News Coverage
IMV logo
IMV
IMV
1.2$3.39-1.5%C$226.16 millionC$3,000.00-5.87
RVX
Resverlogix
0.7$0.89-2.2%C$212.93 millionN/A63.57Upcoming Earnings
News Coverage
FRX
Fennec Pharmaceuticals
0.5$7.85-2.9%C$210.10 millionC$170,000.00-8.21Gap Up
ATE
Antibe Therapeutics
1.3$4.27-6.3%C$206.60 millionC$9.33 million-5.43Gap Down
ONC
Oncolytics Biotech
1.2$3.80-4.7%C$191.02 millionN/A-6.79
IPA
ImmunoPrecise Antibodies
0.4$11.63-5.0%C$123.03 millionC$17.18 million-54.35
HBP
Helix BioPharma
0.5$0.88-3.4%C$119.96 millionN/A-16.00Gap Down
ACST
Acasti Pharma
0.8$0.53-3.8%C$88.79 millionC$81,000.0015.59News Coverage
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.60-1.7%C$66.76 millionC$11.64 million-11.76News Coverage
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.36-4.2%C$58.80 millionC$123,870.00-27.69
PMN
ProMIS Neurosciences
0.5$0.18-0.0%C$55.07 millionC$1,787.00-9.00News Coverage
Gap Down
COV
Covalon Technologies
0.6$1.55-3.2%C$37.44 millionC$23.84 million-6.51
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25-2.0%C$34.02 millionC$13.02 million-0.36
IGX
IntelGenx Technologies
0.9$0.53-1.9%C$30.87 millionC$1.54 million-6.54
QPT
Quest PharmaTech
0.8$0.11-4.8%C$21.76 millionC$38,871.000.16High Trading Volume
Gap Up
CZO
Ceapro
0.7$0.72-2.8%C$21.65 millionC$16.14 million21.82
CTX
Crescita Therapeutics
0.6$0.80-6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20-2.6%C$14.12 millionC$1.34 million-5.57High Trading Volume
GSD
Devonian Health Group
0.5$0.28-7.1%C$13.96 millionC$1.59 million-5.83Gap Down
PAS
Pascal Biosciences
0.6$0.08-6.3%C$12.70 millionN/A-3.64Gap Up
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63-1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.33-3.0%C$10.16 millionC$4.12 million30.00Gap Down
HEM
Hemostemix
0.6$0.34-1.5%C$9.07 millionN/A-2.02Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38-2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17-5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.69-3.5%C$4.48 millionN/A-1.19
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.83-1.6%C$0.00C$267.59 million51.46
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.